Results 41 to 50 of about 252,541 (298)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

, 2022
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia ...
Álvarez-Vallina, Luis, Aguilar-Sopeña, Óscar, Segura-Tudela, Alejandro, Jiménez Reinoso, Anaïs, Rubio-Pérez, Laura, Erce-Llamazares, Ainhoa, Díez-Alonso, Laura, Roda Navarro, Pedro, Morales, Pablo, Paz Artal, Estela Natividad, Ramírez-Fernández, Ángel, Domínguez-Alonso, Carmen, Blanco, Belén   +12 more
core   +1 more source

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies.
Yifan Pang, Nilanjan Ghosh
doaj   +1 more source

Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. [PDF]

, 2008
Contains fulltext : 70575.pdf (Publisher’s version ) (Open Access)Some minor histocompatibility antigens (mHags) are expressed exclusively on patient hematopoietic and malignant cells, and this unique set of antigens enables specific ...
Kelly van den Oudenalder, Mutis, T., Robbert M. Spaapen, Mark F. Leppert, Lokhorst, H.M., Leppert, M.F., Bloem, A.C., Spaapen, R.M., Minnema, M.C., Oudenalder, K. van den, Otterud, B.E., Monique C. Minnema, Tuna Mutis, Mutis, T, Henk M. Lokhorst, Dolstra, H., Andries C. Bloem, Brith E. Otterud, van den Oudenalder, K., Harry Dolstra, Poli Van Creveldkliniek Medisch, Infection & Immunity, Centraal Diagnostisch Laboratorium, Circulatory Health, CTI, Cancer   +25 more
core   +1 more source

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.

PLoS ONE, 2023
T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy.
Piamsiri Sawaisorn, Korakot Atjanasuppat, Kitipong Uaesoontrachoon, Parin Rattananon, Worapapar Treesuppharat, Suradej Hongeng, Usanarat Anurathapan   +6 more
doaj   +2 more sources

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay

Frontiers in Pharmacology, 2023
Introduction: Cellular immunotherapy has greatly improved cancer treatment in recent years. For instance, chimeric antigen receptor (CAR) T cell therapy has been proven highly effective in treating hematological malignancies, and many CAR cell designs ...
YangHao Fu, TianDuo Wang, John A. Ronald, John A. Ronald   +3 more
doaj   +1 more source

Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22
Terry J Fry, Amanda J Novak, Alexander W Rankin, Catherine Pham-Danis, Etienne Danis, M Eric Kohler   +5 more
doaj   +1 more source

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Frontiers in Oncology, 2022
BackgroundThe CAR T-cell therapy is a promising approach to treating hematologic malignancies. However, the application in solid tumors still has many tough challenges, including heterogenicity in antigen expressions and immunosuppressive tumor ...
Yuanyuan Liu, Yanxin Zheng, Tianyi Deng, Yue Huang, Ziwen Liu, Borui Zhan, Xusha Zhou, Runbin Yan, Jiangtao Ren, Yun Xing, Guixing Wu, Biao Zheng, Guang Hu, Wen Wang, Yonghong Liu, Jing Zhao, Xiaoqing Chen, Grace Guoying Zhou   +17 more
doaj   +1 more source

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function

Blood Advances, 2023
Abstract Therapy with CD19-directed chimeric antigen receptor (CAR) T cells has transformed the treatment of advanced B-cell malignancies. However, loss of or low antigen expression can enable tumor escape and limit the duration of responses achieved with CAR T-cell therapy. Engineering bispecific CAR T cells that target 2 tumor antigens
Isabel Leung, Megan L. Templeton, Yun Lo, Anusha Rajan, Sylvia M. Stull, Sarah M. Garrison, Alexander I. Salter, Kimberly S. Smythe, Colin E. Correnti, Shivani Srivastava, Cecilia C. S. Yeung, Stanley R. Riddell   +11 more
openaire   +2 more sources

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source